详情页

资源类型：

文章类型：

作者：

Yang, Sheng[1] * ; Zhang, Yanqiao[2] ; Zhang, Mingjun[3] ; Wu, Yongzhong[4] ; Li, Yongsheng[5] ; Wang, Feng[6] ; Tian, Xin[6] ; Luo, Suxia[7] ; Sun, Yuping[8] ; Wang, Linlin[9] ; Li, Jiancheng[10] ; Jiang, Da[11]

; Wang, Mingxia[11]

; Huang, Yunchao[12] ; Shi, Huaqiu[13] ; Yang, Haiyu[13] ; Liu, Xiaowen[13] ; Ji, Wei[13] ; Pu, Weiqing[13] ; Shi, Yuankai[14] ;

机构： [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China [2]Harbin Medical University Cancer Hospital, Harbin, China [3]The Second Affiliated Hospital of Anhui Medical University, Hefei, China [4]Chongqing University Cancer Hospital, Chongqing, China [5]Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China [6]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [7]Henan Cancer Hospital, Zhengzhou, China [8]Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China [9]Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China [10]Fujian Provincial Cancer Hospital, Fuzhou, China [11]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [12]Yunnan Cancer Hospital, Yunnan, China [13]First Affiliated Hospital Of Gannan Medical University, Ganzhou, China [14]National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

出处：

ISSN：

基金：

语种：

WOS：

中科院分区：

出版当年[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2024]版：

Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

First-in-human study of simmitinib, a novel tyrosine kinase inhibitor targeting FGFR1-3, KDR and CSF-1R

文献详情